Discover in the videos below what it takes to build a European manufacturing facility for cell therapy from scratch, to be ready for tomorrow but also for future developments in cell therapy and how Kite, a Gilead company, takes care to produce a high-quality individualised treatment for patients in high medical need.
Kite, a Gilead company is committed to clinical development of cell-based and other targeted therapies in cancer. The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the European Medicines Agency or other regulatory authorities.
Axicabtagene ciloleucel
Indication:
1L HR LBCL
Axicabtagene ciloleucel
Indication:
2L+ HR FL
Brexucabtagene autoleucel
Indication:
r/r Ped ALL/NHL
Anitocabtagene autoleucel
Indication:
4L r/r Multiple Myeloma
Anitocabtagene autoleucel
Indication:
2-4L r/r multiple myeloma
Latest info as of December 2025, latest info available on https://www.kitepharma.com/cell-therapy/pipeline